Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Paroxysmal Supraventricular Tachycardia · Atrial Fibrillation · MIST

Milestone Pharmaceuticals

Milestone Pharmaceuticals patent portfolio — 12 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
Montreal, CA HQ
2007 Founded
123 Employees
Public company Type
MIST · NYSE Ticker
Company details
Status
Public
HQ
Montreal, CA
Founded
2007
Employees
123
Programs
8
Drugs
6
Patents
12
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Patents

Milestone Pharmaceuticals patents

12 pharmaceutical patents indexed for Milestone Pharmaceuticals. 0 expire within 24 months.

Milestone Pharmaceuticals has 12 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

12 patents

Patent portfolio

  1. US 12257224

    Methods of administration for highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker

    Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10632255

    Drug infusion device

    Expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10308609

    Bicyclic compounds

    Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10251851

    Bicyclic analgesic compounds

    Expires Mon Apr 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10117848

    Highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker and uses thereof

    Expires Mon Nov 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10010524

    Short acting phenylalkylamine calcium channel blockers and uses thereof

    Expires Mon Jun 28 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10010523

    Short acting phenylalkylamine calcium channel blockers and uses thereof

    Expires Mon Jun 28 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10010522

    Short acting phenylalkylamine calcium channel blockers and uses thereof

    Expires Mon Jun 28 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 9737503

    Short acting phenylalkylamine calcium channel blockers and uses thereof

    Expires Mon Aug 17 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 9463179

    Short acting phenylalkylamine calcium channel blockers and uses thereof

    Expires Mon Oct 06 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 9227918

    Short acting phenylalkylamine calcium channel blockers and uses thereof

    Expires Mon Dec 31 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 8501727

    Short acting benzothiazepine calcium channel blockers and uses thereof

    Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Milestone Pharmaceuticals have?

12 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Milestone Pharmaceuticals patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.